Next Article in Journal
Chemical Composition, Bioactivity and Safety Aspects of Kuding Tea—From Beverage to Herbal Extract
Previous Article in Journal
Daily Protein and Energy Intake Are Not Associated with Muscle Mass and Physical Function in Healthy Older Individuals—A Cross-Sectional Study
Open AccessReview

L-Carnitine’s Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

by 1, 1,2 and 1,*,†
1
Department of Food and Nutrition & Research Institute of Obesity Sciences, Sungshin Women’s University, Seoul 01133, Korea
2
Center for Food and Drug Analysis, Gyeongin Regional Korea Food and Drug Administration, Incheon 402835, Korea
*
Author to whom correspondence should be addressed.
The board member of 2020 Korean Dietary Reference Intakes (KDRI).
Nutrients 2020, 12(9), 2795; https://doi.org/10.3390/nu12092795
Received: 5 August 2020 / Revised: 6 September 2020 / Accepted: 10 September 2020 / Published: 12 September 2020
(This article belongs to the Section Micronutrients and Human Health)
A systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to assess L-carnitine supplements’ influence on the biomarkers of metabolic syndrome (MetSyn). PubMed, EMBASE, Cochrane library, and CINAHL were used to collect RCT studies published prior to February 2020. RCT studies were included if they had at least one of the following biomarker outcome measurements: waist circumference (WC), blood pressure (BP), fasting blood sugar (FBS), triglyceride (TG), or high density lipoprotein-cholesterol (HDLc). Nine of twenty studies with adequate methodological quality were included in this meta-analysis. The dose of L-carnitine supplementation administered varied between 0.75 and 3 g/day for durations of 8–24 weeks. L-carnitine supplementation significantly reduced WC and systolic BP (SBP), with no significant effects on FBS, TG, and HDLc. We found that L-carnitine supplementation at a dose of more than 1 g/d significantly reduced FBS and TG and increased HDLc. In conclusion, L-carnitine supplementation is correlated with a significant reduction of WC and BP. A dose of 1–3 g/d could improve the biomarkers of MetSyn by reducing FBS and TG and increasing HDLc. View Full-Text
Keywords: L-carnitine; metabolic syndrome; waist circumference; blood pressure; fasting blood sugar; triglyceride; HDL-cholesterol L-carnitine; metabolic syndrome; waist circumference; blood pressure; fasting blood sugar; triglyceride; HDL-cholesterol
Show Figures

Figure 1

MDPI and ACS Style

Choi, M.; Park, S.; Lee, M. L-Carnitine’s Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2020, 12, 2795.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop